Two-Year Follow-up of Investigator-Initiated Phase 1 Trials of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells (CT053) in Relapsed/Refractory Multiple Myeloma

Siguo Hao, Hong Ma, Songfu Jiang et al.|Blood|2020

Cited by 36